EGFR and non-small cell lung carcinoma: In the CheckMate 057 phase III trial that evaluated nivolumab compared to docetaxel in non-squamous NSCLC patients previously treated with platinum-based chemotherapy, the subgroup of patients with EGFR mutations also did not show benefit from nivolumab [80].